Fed. Circ. Upholds Block On MSN Cancer Drug In Exelixis Win
The Federal Circuit on Monday rejected MSN Laboratories' argument that three Exelixis patents on the blockbuster cancer drug Cabometyx are invalid, while dismissing as moot an appeal on a fourth patent,...To view the full article, register now.
Already a subscriber? Click here to view full article